Lumen
1 known investors
Lumen develops orally-delivered biologic drugs using genetically engineered spirulina algae, which expresses therapeutic proteins such as enzymes, antibodies, and cytokines that are spray-dried into shelf-stable powders and capsules. Its pipeline targets conditions including weight loss, C. difficile, Crohn's disease, ulcerative colitis, and respiratory infections.
Investors Β· 1
Frequently asked questions
- What does Lumen do?
- Lumen develops orally-delivered biologic drugs using genetically engineered spirulina algae, which expresses therapeutic proteins such as enzymes, antibodies, and cytokines that are spray-dried into shelf-stable powders and capsules. Its pipeline targets conditions including weight loss, C. difficile, Crohn's disease, ulcerative colitis, and respiratory infections.
- Who are Lumen's investors?
- Lumen's investors include WestRiver Group.